<DOC>
	<DOCNO>NCT02241369</DOCNO>
	<brief_summary>This Phase I , open-label study evaluate safety , tolerability , immunogenicity INO-3106 alone combination INO-9012 DNA vaccine deliver Electroporation subject HPV6 associate aerodigestive precancerous lesion malignancy .</brief_summary>
	<brief_title>Immunotherapy Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions Malignancies</brief_title>
	<detailed_description>This Phase I , open-label , study evaluate safety , tolerability , immunogenicity 3 mg 6 mg INO-3106 alone combination 1 mg INO-9012 ( DNA plasmid encode human interleukin 12 ) deliver electroporation ( EP ) subject HPV6 associate aerodigestive precancerous lesion malignancy . Subjects enrol 2 cohort ( 3 subject cohort ) : Cohort I : First 3 subject enrol sequentially receive INO-3106 alone combination INO-9012 . Cohort II : The next 3 subject treat 6 mg INO-3106 1 mg INO-9012 , MTD ( Maximum Tolerated Dose ) determine Cohort I .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Signed date write Ethics Committee approve informed consent Age ≥18 year Histologically document HPV6 positive aerodigestive invasive malignancy ( mucosal squamous cell head neck cancer lung cancer ) complete therapy radiation/chemoradiation/chemotherapy ; Histologically document HPV6 positive papilloma HPV6 relate premalignant lesion ( i.e. , carcinoma situ ) aerodigestive head neck region . Prior study entry , subject exhaust treatment are/have use indication may include combination surgery , antiviral therapy , chemotherapy and/or radiation therapy . Core biopsy must obtain prior enrollment confirm invasive cancer . Archival material allow . Adequate bone marrow , hepatic , renal function . ANC ( Absolute Neutrophil Count ) ≥ 1.5x109 cell/ml , platelet ≥75,000 cells/mm3 , hemoglobin ≥ 9.0 g/dL , concentration total serum bilirubin within 1.5 x upper limit normal ( ULN ) , AST , ALT within 2.5x ULN , CPK within 2.5 x ULN , serum creatinine ≤ 1.5x ULN ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Participation clinical trial within 30 day entry Any cardiac preexcitation syndrome , e.g . WolffParkinsonWhite syndrome Presence metal implant within 5 cm plan site ( ) injection Anticipated concomitant immunosuppressive therapy ( exclude nonsystemic inhale , topical skin and/or eye dropcontaining corticosteroid ) Administration vaccine within 6 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Aerodigestive Lesions Malignancies</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
</DOC>